Sino Biopharmaceutical (01177) Publishes February 2026 Monthly Return, No Change to Issued Shares
Bulletin Express
Yesterday
Sino Biopharmaceutical Limited reported that, as of 28 February 2026, the authorized share capital remained at 30.00 billion ordinary shares with a par value of HKD 0.025 each, totaling HKD 750.00 million. The issued share capital stood at 18.76 billion shares, showing no change during the reporting month. The company confirmed compliance with the 25% public float requirement.
An agreement was previously signed in January 2026 for the acquisition of 100% equity interest in Hangzhou Hygieia Biomedical Co., Ltd., partly settled through an allotment of 14.60 million shares. As of February 2026, no new shares have been issued under this agreement, and the total number of treasury shares also remained unchanged.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.